Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 


 
 Table of Contents  
CASE REPORT
Year : 2007  |  Volume : 3  |  Issue : 1  |  Page : 34-36

Bone metastasis from ovarian cancer


Department of Radiotherapy, SGPGI, Lucknow - 226 014, India

Correspondence Address:
Punita Lal
Department of Radiotherapy, SGPGI, Lucknow - 226 014
India
Login to access the Email id


DOI: 10.4103/0973-1482.31969

PMID: 17998717

Get Permissions

 > Abstract 

We report a case of epithelial ovarian cancer, which presented with lumbar vertebral metastasis soon after treatment, as a part of distant spread. This patient was then treated by palliative radiotherapy and put on second line chemotherapy i.e., Topotecan. She responded to treatment well.

Keywords: Bone metastsis, cancer ovary


How to cite this article:
Tiwari A, Kumar N, Bajpai R, Lal P. Bone metastasis from ovarian cancer. J Can Res Ther 2007;3:34-6

How to cite this URL:
Tiwari A, Kumar N, Bajpai R, Lal P. Bone metastasis from ovarian cancer. J Can Res Ther [serial online] 2007 [cited 2014 Oct 23];3:34-6. Available from: http://www.cancerjournal.net/text.asp?2007/3/1/34/31969


 > Introduction Top


Ovarian cancer is the fourth most common type of female cancer and fifth leading cause of cancer death in women in the United States.[1] In India, the ICMR registry reports the crude incidence rate of this cancer as 4.2 per 100,000 women, making it the fourth most common malignancy in women.[2] Main route of dissemination in ovarian cancer is by transcoelomic spread and through lymphatics. Hematogenous spread is uncommon.[3],[4]

Metastasis to bones from these tumors is rare (0.1-0.12%) and is reported in a few series.[5],[6] We have registered 189 ovarian cancers in the department of radiotherapy, SGPGI, in the last 15 years and have not encountered single case of bone metastasis so far. This case was unique in presenting vertebral metastasis soon after chemotherapy.


 > Case Report Top


A 45-year-old premenopausal lady presented to a local gynecologist with chief complaints of distention of abdomen, loss of appetite and vague abdominal discomfort for three months duration. There was no associated menstrual complaint. An ultrasound of the abdomen and pelvis was done, which revealed bilateral mixed solid and cystic adenaxal masses along with ascitis and a large solitary peritoneal implant. A tentative diagnosis of ovarian malignancy was made, based on which Total abdominal hysterectomy and bilateral salpingooopherectomy (TAH-BSO) was done. Histopathology report of the specimen showed mucinous papillary cystic adenocarcinoma in both the ovaries. Uterus, cervix and fallopian tube were free and the omental deposit was positive for malignancy. The patient was staged as having Stage IIIC ovarian cancer (as per FIGO 1986 staging system). She was advised for adjuvant chemotherapy at that time, which she did not take. Three months later she developed distention of abdomen along with vague dyspeptic symptoms. She then reported to the Department of Radiotherapy Sanjay Gandhi Postgraduate Institute of Medical Sciences for further management.

On examination at that time, she was of average built with karnofsky performance status of 80. There was no evidence of pallor, icterus or lymphadenopathy. Examination of abdomen showed presence of free fluid with no associated organomegaly or palpable lump. Pouch of Douglas was free on per vaginal examination. She was investigated with a contrast-enhanced computed tomography (CECT) scan of abdomen and pelvis, which showed moderate ascitis with no residual disease or enlarged pelvic or para aortic lymph nodes and had postoperative changes.

CA 125 was done at that time and it was raised to 510U/ml. She was diagnosed to have progression of disease. Adjuvant chemotherapy i.e., Paclitaxel and Cisplatin was planned. She received six cycles of Paclitaxel (175 mg/m 2 ) and Cisplatin (75 mg/m 2 ) at three weekly intervals. The patient was hospitalized for chemotherapy, which was given with proper hydration and under antiemetic cover. She tolerated chemotherapy well and was on regular follow-up thereafter. Her CA-125 levels came down to 24U/ml at the end of treatment. Five months after completion of treatment, she complained of backache and abdominal pain and was advised for X-ray lumbar spine, bone scan, liver scan and CECT scan of abdomen. X-ray-lateral view [Figure - 1] and bone scan [Figure - 2] revealed a solitary metastasis on L2 vertebra. CECT scan of the abdomen [Figure - 3] showed a space occupying lesion in the postero-medial aspect of right lobe of liver suggestive of solitary liver metastasis and the finding of which was confirmed on liver scan. CA 125 level was 210U/ml. She received palliative radiotherapy to lumbar spine (8 Gy in one fraction). Second line salvage chemotherapy was planned in the form of Injection Topotecan (1.5 mg/m 2 ) D1to 5. She is presently on this schedule, is tolerating it well and has obtained 80-90% symptomatic benefit.


 > Discussion Top


Epithelial ovarian cancer should not be considered a disease that remains confined to the pelvis and abdomen. Like other adenocarcinomas this disease has significant potential for distant metastasis.[3] Bony metastasis from epithelial ovarian malignancies is anecdotal and has been reported rarely in literature. Mode of spread appears to be hematogenous although no definite route has been documented in literature.

In an autopsy series, Dauplat et al analyzed 336 patients of distant metastasis from ovarian cancers. Of these, four patients had bone metastasis, two of which belonged to thoracic vertebra; one to the clavicle and one had bone marrow involvement. None of the patients in this series had bone metastasis as first site of presentation. According to the authors bony metastasis is rarest to be presented as first site and median time to development ranged from 13-49 months.[3] In the present case report as well, bone involvement appears to be a part of hematogenous spread since both liver and bone were involved.

Rose et al in their autopsy series studied the metastatic pattern in 428 ovarian cancers and correlated different histologies with sites of metastasis. The incidence of bony metastasis was 0.06-0. 19% with epithelial histology. This reflects the rarity of bone involvement in this malignancy. There was no difference, however, in the spread pattern with different histological subtypes.[5]

Fadi et al did a clinico pathological audit of bone metastasis from different gynecological carcinomas. They analyzed 305 patients, of which 113 were ovarian cancers. Skeletal metastasis was seen in seven patients. Five were documented as postmortem findings and only two showed up radiologically and in premortem setting. Bone metastasis was seen in high grades tumors only. Most common site observed was thoracic vertebra, followed by clavicle and axial skeleton.[7]

In the present case too, high-grade features were documented in the TAH-BSO specimen. Lumbar vertebral involvement, which is less common than thoracic region, was seen in this case.

Rose et al had observed that presence of lymph nodes within the pelvis and para aortic regions were associated with greater incidence of bone metastasis as compared to absent lymphadenopathy i.e., 0.14% to 0.02%.[5] The present case did not have any lymph nodes yet bony secondaries developed five months following treatment.

Although there was no histological proof of spread to the vertebra but radiological and scintigraphic evidence was considered sufficient proof of dissemination to the bone. Pain palliation and growth restraint was done as one would do in any epithelial malignancy. Radiotherapy along with single agent Topotecan has been found to be effective thus far.

 
 > References Top

1.Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. Cancer J Clin 2003;53:5-26.  Back to cited text no. 1
    
2.Biennial Report (1990-96) of National Cancer Registry Programme, Indian Council of Medical Research: New Delhi; Nandkumar A, editor. Publ National Printing Press: Bangalore; 2001. p. 62-3.  Back to cited text no. 2
    
3.Dauplat J, Hacker NF, Nieberg RK, Berek SJ, Rose PT, Sagae S. Distant metastasis in epithelial ovarian carcinoma. Cancer 1987;60:1561-6.   Back to cited text no. 3
    
4.Dvoretsky PM, Richards KA, Bonfiglio TA. The pathology and biologic behavior of ovarian cancer. An autopsy review. Pathol Ann 1989;24:1-24.  Back to cited text no. 4
    
5.Rose PG, Piver SM, Tsukada Y, Lau TS. Metastatic patterns in histologic variants of ovarian cancer: An autopsy study. Cancer 1989;64: 1508-13.  Back to cited text no. 5
    
6.Julian CG, Goss J, Blanchard K, Woodruff JD. Biologic behavior of primary ovarian malignancy. Obstet Gynecol 1974;44:873-84.  Back to cited text no. 6
[PUBMED]    
7.Abdul-Karim FW, Kida M, Wentz WB, Carter JR, Sorensen K, Macfee M, et al . Bone metastasis from gynecologic carcinomas: A clinicopathologic study. Gynecol Oncol 1990;39:108-14.  Back to cited text no. 7
[PUBMED]    


    Figures

  [Figure - 1], [Figure - 2], [Figure - 3]


This article has been cited by
1 Destructive T10 vertebral lesion leads to diagnosis of metastatic ovarian cancer
Ryan J. Callery,Elizabeth Burton,Alok Sharan,Reza Yassari,Gary L. Goldberg
Gynecologic Oncology Case Reports. 2013; 4: 1
[Pubmed]
2 Bone metastases from gynaecological epithelial cancers
L. Gottwald, A. Dukowicz, J. Piekarski, B. Misiewicz, M. Spych, P. Misiewicz, S. Kazmierczak-Lukaszewicz, M. Moszynska-Zielinska, A. Cialkowska-Rysz
Journal of Obstetrics & Gynaecology. 2012; 32(1): 81
[VIEW]
3 Recurrent Ovarian Carcinoma Presenting as a Solitary Sternal Metastasis on FDG PET/CT :
Linh Ho, Aarti Kaushik, Weifang Zhang, Heidi Wassef
Clinical Nuclear Medicine. 2011; 36(8): 733
[VIEW]
4 Impact of bowel obstruction at the time of initial presentation in women with ovarian cancer
Rauh-Hain, J.A., Del Carmen, M., Horowitz, N.S., Alarcon, I.A., Ko, E., Goodman, A.K., Olawaiye, A.B.
BJOG: An International Journal of Obstetrics and Gynaecology. 2010; 117(1): 32-38
[Pubmed]
5 Antimetastatic activity of MONCPT in preclinical melanoma mice model
Xiao-Chun Yang, Chong-Xing Tu, Pei-Hua Luo, Hong Zhu, Di-Feng Zhu, Hong-Hai Wu, Xing-Lu Zhou, Wei Lu, Qiao-Jun He, Bo Yang
Investigational New Drugs. 2010; 28(6): 800
[VIEW]
6 Impact of bowel obstruction at the time of initial presentation in women with ovarian cancer
JA Rauh-Hain,M del Carmen,NS Horowitz,IA Alarcon,E Ko,AK Goodman,AB Olawaiye
BJOG: An International Journal of Obstetrics & Gynaecology. 2010; 117(1): 32
[Pubmed]



 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

  >Abstract>Introduction>Case Report>Discussion>Article Figures
  In this article
>References

 Article Access Statistics
    Viewed21306    
    Printed248    
    Emailed5    
    PDF Downloaded705    
    Comments [Add]    
    Cited by others 6    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]